The Neuro-Oncology Translational Research Training Program aims to bridge laboratory discoveries and clinical applications in neuro-oncology, targeting glioblastoma and brain metastases. The program provides predoctoral and postdoctoral trainees with cutting-edge lab experience and mentorship across multiple disciplines.
A new study published in Neuro-Oncology found that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously thought. The study suggests that doctors may need to rethink current screening guidelines for detecting brain metastasis in patients without symptoms.
Jeremy L. Davis, MD, has been appointed as the new Surgical Oncology Lead for UMGCCC and Chief of the Division of Surgical Oncology in the Department of Surgery at UMSOM. Dr. Davis is a nationally recognized surgical oncologist with expertise in gastric cancer research.
The Fourth Transatlantic Exchange in Oncology Conference will focus on Radiopharmaceutical Therapy Meets Oncology, with key presentations on precision oncology and radioligand therapies. The meeting aims to facilitate the exchange of information and talents toward one goal: curing cancer.
NRG Oncology has established a new Theranostics Subcommittee to develop a more robust theranostics program within its portfolio. The subcommittee will serve as a resource for research investigators and collaborate with other organizations to enhance the effects of treatment on targeted cancer.
A Phase III clinical trial found that stereotactic body radiotherapy (SBRT) added to sorafenib improved progression-free survival and overall survival in patients with locally advanced hepatocellular carcinoma, particularly those with macrovascular invasion. The study also showed improvements in quality of life for these patients.
Researchers analyzed data from 11,797 adults with advanced solid cancers and found no difference in mortality rates during the shortage period. Prescription rates for cisplatin and carboplatin fell less than three percent overall, with alternative therapies helping mitigate the crisis.
The European Society of Cardiology emphasizes the importance of including heart and cardiovascular health in cancer treatment plans. Recent studies estimate that approximately one-third of patients experience mild toxicities, while 3% develop moderate toxicity. The ESC is launching a new conference to address this growing epidemic.
A team of UNC-Chapel Hill researchers will develop an oncology health learning system using AI-ready data to generate real-time identification of new cancer cases and support personalized treatments. The project aims to improve cancer diagnosis, care equity, and quality by creating accessible tools for health providers.
The ESMO Immuno-Oncology Congress 2024 will present key findings on new therapeutic opportunities and management of treatment-related toxicities. Leading experts will share their research advancements in the rapidly evolving field of immuno-oncology.
The Gustave Roussy Prize recognizes scientists whose work improves cancer treatment and patient outcomes. Established by Pierre Fabre Laboratories, the €200,000 award aims to push boundaries of oncology and offer personalized treatments.
The National Comprehensive Cancer Network (NCCN) is collaborating with leading cancer centers in China to improve cancer treatment and outcomes. NCCN Guidelines provide evidence-based recommendations for cancer treatment, prevention, and supportive care, guiding high-quality care globally.
Neuro-oncology experts developed guidelines to standardize AI use in brain cancer diagnosis and treatment. The recommendations aim to ensure reliable clinical trial results and protect patients.
Tiffany Richards, a seasoned oncology nurse supervisor, receives the prestigious award for her exceptional patient care and dedication to clinical excellence. She joins an elite group of nursing professionals who have made significant contributions to advancing cancer treatment.
The NRG Oncology trial found that atezolizumab given concurrently with chemoradiation did not improve overall survival for patients with limited-stage small cell lung cancer. However, the study suggests that LS-SCLC patients benefit from immunotherapy when given after completion of chemoradiation.
A randomized trial halted after patients in the control arm reached a record high two-year progression-free survival rate of 98%. Deintensified treatments involving lower radiation dose and immunotherapy did not perform as well as standard chemoradiation.
UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.
Leading researchers from Penn Medicine will showcase clinical trial results and new data on FLASH radiation therapy. The institution is one of the world’s leading academic medical centers, with a proud history of groundbreaking discoveries and innovations.
The Cancer Cooperative Group System is being re-engineered to bring new money to correlative science research through public-private partnerships, aiming to remove barriers for researchers to access biological samples. This will facilitate the integration of innovative science into cancer clinical trials.
A new study from NRG Oncology found that whole-breast irradiation (WBI) was not statistically equivalent to accelerated partial-breast irradiation (APBI) in local tumor control. The QOL sub-study also showed that APBI may be preferred by some patients due to reduced fatigue and extended treatment time.
A new study published in Annals of Oncology found that long-course radiotherapy is safer and more effective than short-course radiotherapy for preserving organs in rectal cancer patients. The treatment was shown to prevent regrowth of the primary tumour, but had similar overall survival rates.
Researchers found that adding metastasis-directed radiation therapy to standard chemotherapy improved progression-free survival by 7.8 months in patients with oligometastatic pancreatic cancer. The approach also showed increased immune responses and longer survival times.
A year-long pilot program found that external mentorship increased confidence, furthered career development, and facilitated networking opportunities for trainees in classical hematology. The program paired hematology/oncology fellows with mentors outside their institutions to meet virtually each month.
A new AI protocol called DeepHRD enables accurate, instantaneous detection of cancer genomic biomarkers directly from tumor biopsy slides. This breakthrough technology saves weeks and thousands of dollars from clinical oncology treatment workflows, providing access and equity in cancer care for resource-constrained settings.
A new study found that two Medicaid policies can interact to increase oncology clinical trial enrollment among Black and Hispanic patients. Medicaid expansion under the ACA alone did not improve diversity, but states with pre-existing mandates requiring coverage of clinical trial costs saw a significant increase.
New article outlines considerations for clinical trial design to enhance OS collection and analysis. Key findings include the importance of prespecified statistical analyses of OS as a safety endpoint and robust assessments to support approval.
A recent study published in the Journal of Clinical Oncology found that combining different chemotherapy drugs improves testicular cancer's treatability and often curability, even after first-line treatment fails. The study showed a nearly 80% response rate and no significant drop-off in survival over 10 years.
The study establishes criteria for identifying extranodal extension on imaging, allowing radiologists to make accurate calls and provide patients with less invasive treatments. This shift towards practice change has the potential to reduce side effects and improve outcomes for patients with HPV-associated head and neck cancers.
A study by UC Irvine found that the ePRO tool improved symptoms management for Hispanic and Asian patients undergoing chemotherapy, reducing pain, nausea, and vomiting. The tool, which uses real-time analytics and personalized treatment plans, also increased patient satisfaction.
The article reviews recent advances in applying artificial intelligence to oncology, showcasing promising improvements in cancer care. The authors emphasize the need for interdisciplinary collaboration, rigorous validation, and ethical principles to harness AI's potential.
Researchers at MD Anderson Cancer Center found fewer side effects with intensity-modulated radiotherapy (IMRT), with similar survival outcomes compared to 3D-CRT. The study validated heart exposure as an important radiation planning objective, revealing better five-year overall and progression-free survival rates for IMRT.
St. Jude researchers found that early surveillance after genetic predisposition discovery detects new, treatable tumors in 70% of cases. This approach can avoid chemotherapy and radiation, improving outcomes for children with cancer.
The American Society for Radiation Oncology (ASTRO) has published an updated clinical guideline for treating patients with HPV-related oropharyngeal squamous cell carcinoma. The guideline emphasizes the importance of tailored radiation strategies to maximize patient survival while minimizing side effects. It provides recommendations fo...
The American Society for Radiation Oncology has released new guidelines for radiation therapy in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), recommending optimal dosing regimens to reduce acute and late effects. Concurrent chemotherapy with cisplatin is recommended for more advanced tumors or multiple lymph nodes.
The NRG-RTOG 0848 clinical study found that adding chemoradiation to adjuvant systemic therapy improves overall survival for node-negative pancreatic cancer patients, but not for those with node-positive disease. Disease-free survival was also improved in both groups.
A study published in Frontiers in Oncology reveals breast cancer incidence has surged in oil-rich Gulf countries, with unique clinical and pathological features. The disease is attributed to a combination of menstrual cycle, hereditary factors, weaning children earlier than expected, hormonal treatment, obesity, and use of contraceptives.
Researchers found disparities in LGBTQ+ patient experiences, including discomfort with disclosure and lack of partner respect. International medical graduates face unconscious bias, limited opportunities, and financial stress, affecting their engagement with healthcare systems.
Sharon Giordano and Richard Gorlick will be honored with Special Awards at the 2024 American Society of Clinical Oncology Annual Meeting for their dedication to improving cancer treatment and patient outcomes. Their research has made significant contributions to the field of oncology, with a focus on breast cancer and pediatric oncology.
The updated clinical guideline recommends multiple dose-fractionation schemes to relieve pain and symptoms of bone and spine lesions. Advanced radiation techniques like intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) are now routine clinical care for many patients.
The study found a 5.7% blood culture positive rate among eligible Hem-Onc patients, with 56% having an absolute neutrophil count greater than 500 µL at presentation. Gram-positive organisms were the most common isolates, highlighting the diversity of bloodstream infection causes in this patient population.
The American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting will be held in Washington, D.C., featuring over 170 exhibitors showcasing state-of-the-art cancer care technologies. Registered attendees can access livestreams of scientific and educational sessions, both in-person and virtually.
The NCCN 2024 Annual Conference shared updates on improving cancer care worldwide, including plenary sessions on drug shortages and hereditary cancer risk. Key takeaways include the need for transparency around oncology supply chains and the importance of genetic testing to reduce cancer risk.
Two new Review articles explore AI's application in early cancer detection, highlighting its potential to enhance diagnostic accuracy and improve treatment selection. The articles emphasize the need for a robust, multi-disciplinary approach to integrate AI into medicine.
A Northwestern University study found ChatGPT's responses to radiation oncology patient questions were on par or exceeded professional society answers. The AI technology aims to empower patients before and after seeing physicians, while also reducing clinician burnout.
The DTEP model accurately predicts delayed treatment effects (DTE) in immuno-oncology trials, allowing for optimized trial designs. By tailoring trial lengths, the model enhances statistical power and accelerates immunotherapy development.
A new acceptable practice standard for hypofractionated post-prostatectomy radiotherapy has been established based on the NRG Oncology trial findings. The study showed that HYPORT was non-inferior to COPORT in terms of late GI or GU toxicity, with greater short-term GI toxicity associated with HYPORT but resolving at 6 months following...
Alex Jaeger, a Moffitt Cancer Center researcher, has received the Damon Runyon-Rachleff Innovation Award for his project on exploiting MHC-II antigen presentation in cancer. His goal is to develop advanced immunotherapeutic strategies by understanding how distinct patterns of antigen presentation trigger specific T-cell pathways.
A study published in JAMA Oncology found that MRI monitoring in women with BRCA1 mutations significantly reduces breast cancer mortality without the need for preventive mastectomy. The research included data from 2,488 women and showed a notable decrease in mortality rate among participants.
A new study found that many newly approved EU oncology drugs lack proof of added benefit, with over half recovering R&D costs within three years. This challenges the industry's claim that high drug prices are necessary to offset R&D expenses.
A study found that over half of cancer drugs approved through expedited pathways recover research and development costs within three years, despite lacking proof of added benefit. The researchers emphasize the need for better alignment between regulatory and reimbursement processes to promote effective drug development.
Researchers created Elenagen, a novel DNA immunotherapy for deadly ovarian cancer, which significantly enhances standard chemotherapy and provides clinical benefits. The study shows that Elenagen delays disease progression in patients with stage III and IV platinum-resistant ovarian cancer.
A new study evaluates AI algorithms for autocontouring prior to radiotherapy in head and neck cancer. OpenAI's GPT-4-turbo demonstrated the best performance, while Llama-2 models underperformed. The study highlights the potential of generative AI to revolutionize radiation oncology education and practice.
A new machine learning model, COLOXIS, uses data from two NSABP clinical trials to predict which colon cancer patients will benefit from the addition of oxaliplatin. The model shows that patients with a signature-positive prediction can derive benefit from oxaliplatin, while those with a signature-negative prediction do not.
Dr. Eric Topol predicts that cancer screening will be transformed by AI in the next couple of years, with improved diagnosis accuracy and access to GPT support for doctors.
Liquid biopsies have the potential to monitor therapy success and predict tumor recurrence in high-risk neuroblastoma patients. The MONALISA project aims to establish liquid biopsies as a standard procedure for monitoring relapsed neuroblastoma, offering hope for improved personalized medicine.
A Phase 2B clinical trial, led by City of Hope, found that carvedilol may improve heart health markers and reduce the risk of heart failure in childhood cancer survivors. The study suggests that carvedilol could benefit long-term survivors and those who are highly adherent to the treatment.
Recent review highlights the potential of AGI in radiotherapy, enabling advanced auto-segmentation, tumor staging, and treatment planning. The fusion of vision data with large language models creates powerful multimodal models that elucidate nuanced clinical patterns.
A study published in the Journal of Thoracic Oncology found that adopting a lung nodule program can increase early lung cancer detection for patients not eligible for traditional screening. The study revealed significant differences in stage at diagnosis and overall survival rates between young, elderly, and screened cohorts.
A recent study published in The Lancet Oncology found that the risk of dying from cancer in some poorer districts of England is over 70% higher than in wealthier areas. The study used death records to estimate the risk of dying from various cancers in each district, highlighting significant inequalities in cancer mortality across diffe...
Bioethics researchers at Dana-Farber Cancer Institute warn that patient-facing AI can depersonalize care and erode relationships between patients and caregivers. The authors advocate for principles such as human dignity, patient autonomy, and regulatory oversight to ensure AI-driven healthcare is ethically sound and equitable.